Abstract
A third Comirnaty® vaccine dose increased SARS-CoV-2-receptor binding domain antibody levels (median of 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (median, 22-fold), Delta, (median, 43-fold) and Omicron (median, 8-fold) variants, particularly in SARS-CoV-2-naïve individuals, but had a negligible impact on S-reactive T-cell immunity in nursing home residents.
Keywords: SARS-CoV-2, Comirnaty® COVID-19 vaccine third dose, SARS-CoV-2-S antibodies, SARS-CoV-2-S T cells, neutralizing antibodies, nursing home residents
Contributor Information
Estela Giménez, Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Eliseo Albert, Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Joao Zulaica, Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Ignacio Torres, Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Luciana Rusu, Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Alicia Rodríguez Moreno, Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Javier S Burgos, General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.
Salvador Peiró, Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
Dolores Salas, Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain; General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
Hermelinda Vanaclocha, General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
Ramón Limón, General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain.
María Jesús Alcaraz, Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
José Sánchez-Payá, Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.
Javier Díez-Domingo, Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
Iñaki Comas, Biomedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain; CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain.
Fernando Gonzáles-Candelas, Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain; CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain.
Ron Geller, Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
David Navarro, Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
Supplementary Material
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.